Michel D Ferrari Selected Research

Neurotransmitter Agents (Neurotransmitter)

6/2017	Inhibition of the P2X7-PANX1 complex suppresses spreading depolarization and neuroinflammation.
9/2010	Severe and progressive neurotransmitter release aberrations in familial hemiplegic migraine type 1 Cacna1a S218L knock-in mice.
7/2009	Molecular genetics of migraine.
9/2008	Enhanced circadian phase resetting in R192Q Cav2.1 calcium channel migraine mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michel D Ferrari Research Topics

Disease

90	Migraine Disorders (Migraine) 05/2024 - 01/2002
37	Migraine with Aura (Familial Hemiplegic Migraine) 01/2023 - 09/2003
17	Epilepsy (Aura) 01/2023 - 01/2004
13	Headache (Headaches) 01/2020 - 02/2005
12	Pain (Aches) 01/2015 - 01/2002
10	Cluster Headache (Cluster Headaches) 12/2022 - 11/2013
6	Stroke (Strokes) 12/2019 - 02/2006
4	Migraine without Aura (Common Migraine) 01/2021 - 11/2008
4	Ischemic Stroke 10/2020 - 01/2012
4	CADASIL 01/2018 - 12/2010
3	Infarction (Infarctions) 10/2020 - 01/2012
3	Leukoencephalopathies 01/2018 - 11/2016
3	Ataxia (Dyssynergia) 01/2009 - 12/2006
2	Seizures (Absence Seizure) 01/2022 - 01/2009
2	visual snow syndrome 01/2021 - 07/2019
2	5 Familial Hemophagocytic Lymphohistiocytosis 01/2021 - 06/2016
2	Prescription Drug Overuse 01/2020 - 01/2019
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2018 - 12/2017
2	Cerebral Small Vessel Diseases 01/2018 - 12/2012
2	Disease Progression 01/2018 - 03/2002
2	Neuroinflammatory Diseases 08/2017 - 06/2017
2	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2017 - 01/2016
2	Inflammation (Inflammations) 01/2016 - 02/2013
2	Cerebellar Ataxia (Dysmetria) 03/2014 - 10/2012
2	Photophobia (Light Sensitivity) 08/2013 - 12/2008
2	Headache Disorders (Headache Syndromes) 07/2012 - 06/2005
2	Muscle Weakness 04/2007 - 03/2002
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022
1	Brain Edema (Cerebral Edema) 01/2022
1	Transient Ischemic Attack 10/2020
1	Ischemia 10/2020
1	Brain Ischemia (Cerebral Ischemia) 10/2020

Drug/Important Bio-Agent (IBA)

24	voltage-dependent calcium channel (P-Q type)IBA 01/2022 - 03/2004
11	Biomarkers (Surrogate Marker)IBA 01/2019 - 07/2006
9	Tryptamines (Triptans)IBA 01/2020 - 01/2003
9	Calcium Channels (Calcium Channel)IBA 01/2017 - 06/2002
8	Pain-FreeIBA 07/2012 - 02/2005
7	Glutamic Acid (Glutamate)FDA Link 01/2021 - 06/2007
7	Retinaldehyde (Retinal)IBA 01/2018 - 06/2008
7	frovatriptan (Allegro)FDA Link 07/2012 - 06/2010
6	Calcitonin Gene-Related PeptideIBA 10/2020 - 12/2008
5	Valproic Acid (Depakote)FDA LinkGeneric 01/2022 - 01/2010
5	zolmitriptan (Zomig)FDA Link 05/2012 - 12/2008
4	erenumabIBA 05/2024 - 11/2018
4	Type A Botulinum Toxins (Botox)FDA Link 01/2022 - 01/2019
4	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2022 - 10/2011
4	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2021 - 01/2020
4	Analgesics (Analgesic Drugs)IBA 01/2021 - 06/2005
4	Sumatriptan (Imigran)FDA LinkGeneric 01/2020 - 01/2002
4	Neurotransmitter Agents (Neurotransmitter)IBA 06/2017 - 09/2008
4	Proteins (Proteins, Gene)FDA Link 06/2016 - 09/2012
4	Adenosine Triphosphatases (ATPase)IBA 09/2012 - 09/2003
4	almotriptan (Axert)FDA Link 07/2012 - 01/2002
4	rizatriptan (Maxalt)FDA Link 05/2012 - 01/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 05/2007
3	Topiramate (Topamax)FDA LinkGeneric 01/2022 - 01/2010
3	RNA (Ribonucleic Acid)IBA 01/2021 - 03/2014
3	salicylhydroxamic acid (SHAM)IBA 10/2019 - 01/2018
3	Lamotrigine (Lamictal)FDA LinkGeneric 07/2019 - 08/2014
3	telcagepantIBA 02/2016 - 12/2008
3	Hormones (Hormone)IBA 01/2015 - 02/2013
3	Vasoconstrictor AgentsIBA 10/2010 - 01/2004
3	PotassiumIBA 11/2008 - 06/2004
3	Sodium Channels (Sodium Channel)IBA 07/2008 - 07/2005
2	gamma-Aminobutyric Acid (GABA)IBA 01/2023 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2022 - 01/2015
2	Monoclonal AntibodiesIBA 01/2022 - 01/2016
2	fremanezumabIBA 01/2022 - 01/2019
2	Q-Type Calcium Channels (Q-Type Calcium Channel)IBA 01/2022 - 04/2014
2	Illicit Drugs (Recreational Drugs)IBA 01/2021 - 01/2019
2	Vasodilator Agents (Vasodilators)IBA 01/2020 - 01/2015
2	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 11/2018 - 12/2008
2	AndrogensIBA 01/2018 - 10/2009
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2018 - 02/2013
2	Capsaicin (Zostrix)FDA Link 01/2018 - 01/2015
2	IronIBA 07/2017 - 12/2012
2	Purinergic P2X3 ReceptorsIBA 01/2013 - 08/2010
2	Voltage-Gated Sodium ChannelsIBA 07/2008 - 07/2005
2	eletriptan (Relpax)FDA Link 02/2008 - 01/2002
1	tetraethylpyrazine (TEP)IBA 01/2023
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2023
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2023
1	Arginine (L-Arginine)FDA Link 01/2023
1	AminesIBA 01/2023
1	3-methylmethcathinoneIBA 01/2021
1	Nitrous Oxide (Laughing Gas)IBA 01/2021
1	c-Mer Tyrosine KinaseIBA 01/2021
1	A 7 (A-7)IBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2021
1	Hallucinogens (Psychedelics)IBA 01/2021
1	4-fluoroamphetamineIBA 01/2021
1	Psilocybin (Psilocibin)IBA 01/2021
1	rimegepant sulfateIBA 10/2020
1	olcegepantIBA 10/2020
1	Oxygen (Dioxygen)IBA 01/2020

Therapy/Procedure

12	Therapeutics 12/2022 - 02/2005
4	Vagus Nerve Stimulation 10/2020 - 01/2018
2	Lasers (Laser) 01/2015 - 01/2012
1	Injections 02/2022